View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 4, 2018

Inovio and GeneOne dose first patient in Phase l trial of GLS-6150

Inovio Pharmaceuticals and GeneOne Life Science have dosed the first patient in a Phase l trial of GLS-6150 for the treatment of hepatitis C.

Inovio Pharmaceuticals and GeneOne Life Science have dosed the first patient in a Phase l trial of GLS-6150 for the treatment of hepatitis C.

Developed jointly by both companies, the open-label trial is designed to investigate the ability of GLS-6150 to enhance immunity in people who have been treated and cleared of hepatitis C virus.

The trial is expected to examine 24 people with a sustained virologic response (SVR) following treatment for Hepatitis C and an additional eight healthy controls to compare immune responses.

During the trial, the participants will receive one of two doses (1mg or 2mg) of the GLS-6150 vaccine, which will be given intra-dermally and followed by electroporation with Cellectra-3P device.

Vaccinations will be given as a three-dose priming series at 0, 4, and 12 weeks, or as a two dose priming series at 0 and 8 weeks. They will be followed by a booster dose at six months.

“The key to a successful hepatitis C vaccine will be its ability to activate the body’s immune system to prevent or treat infection by a virus with multiple or ever-changing strains.”

The final study visit is four weeks after the six-month booster vaccination.

The trial has already started patient enrolment in South Korea, where GeneOne is responsible for performing and funding the trial.

Inovio Pharmaceuticals president and CEO Dr J Joseph Kim said: “Developing the first successful vaccine against hepatitis C virus is a highly ambitious endeavour but a truly impactful effort for global health as well as being transformative for us commercially.

“The key to a successful hepatitis C vaccine will be its ability to activate the body’s immune system to prevent or treat infection by a virus with multiple or ever-changing strains.

“Inovio’s innovative DNA-based technology platform is uniquely positioned to address this challenge and it has been optimising over the last several years in demonstrating strong in vivo immune responses against very tough-to-treat viruses like HIV, Zika and flu.”

Data from the Phase l trial is expected to be available next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena